Affordable Access

Access to the full text

Optimization of the antibiotic management of diabetic foot infections: protocol for two randomized controlled trials

Authors
  • Waibel, Felix1
  • Berli, Martin1
  • Catanzaro, Sabrina1
  • Sairanen, Kati1
  • Schöni, Madlaina1
  • Böni, Thomas1
  • Burkhard, Jan1
  • Holy, Dominique1
  • Huber, Tanja1
  • Bertram, Maik1
  • Läubli, Karin1
  • Frustaci, Dario1, 1
  • Rosskopf, Andrea1
  • Botter, Sander1
  • Uçkay, Ilker1, 2
  • 1 Balgrist University Hospital, Zurich, Switzerland , Zurich (Switzerland)
  • 2 Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland , Zurich (Switzerland)
Type
Published Article
Journal
Trials
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 08, 2020
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s13063-019-4006-z
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundFew studies have addressed the appropriate duration of antibiotic therapy for diabetic foot infections (DFI) with or without amputation. We will perform two randomized clinical trials (RCTs) to reduce the antibiotic use and associated adverse events in DFI.MethodsWe hypothesize that shorter durations of postdebridement systemic antibiotic therapy are noninferior (10% margin, 80% power, alpha 5%) to existing (long) durations and we will perform two unblinded RCTs with a total of 400 DFI episodes (randomization 1:1) from 2019 to 2022. The primary outcome for both RCTs is remission of infection after a minimal follow-up of 2 months. The secondary outcomes for both RCTs are the incidence of adverse events and the overall treatment costs. The first RCT will allocate the total therapeutic amputations in two arms of 50 patients each: 1 versus 3 weeks of antibiotic therapy for residual osteomyelitis (positive microbiological samples of the residual bone stump); or 1 versus 4 days for remaining soft tissue infection. The second RCT will randomize the conservative approach (only surgical debridement without in toto amputation) in two arms with 50 patients each: 10 versus 20 days of antibiotic therapy for soft tissue infections; and 3 versus 6 weeks for osteomyelitis. All participants will have professional wound debridement, adequate off-loading, angiology evaluation, and a concomitant surgical, re-educational, podiatric, internist and infectiology care. During the surgeries, we will collect tissues for BioBanking and future laboratory studies.DiscussionBoth parallel RCTs will respond to frequent questions regarding the duration of antibiotic use in the both major subsets of DFIs, to ensure the quality of care, and to avoid unnecessary excesses in terms of surgery and antibiotic use.Trial registrationClinicalTrials.gov, NCT04081792. Registered on 4 September 2019.

Report this publication

Statistics

Seen <100 times